Cost burden of diffuse large B-cell lymphoma

Harkins, R. Andrew; Patel, Sharvil P.; Flowers, Christopher R.

doi:10.1080/14737167.2019.1680288

Cited by 15 publications

(12 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously mentioned, IMRT may contribute more to lymphopenia, which may actually be helpful during manufacturing in an effort to make room for eventual CAR T-cell infusion. Additionally, proton therapy could contribute to the rising cost of treatment, which is already quite substantial with CAR T-cell treatment [ 55 ]. Therefore, careful exploration for using proton therapy in CAR T-cell treatment is needed, such as on a clinical trial or registry [ 56 ].…”

Section: Role For Proton Therapymentioning

confidence: 99%

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Saifi

Kharfan‐Dabaja

Zeidan

et al. 2020

International Journal of Particle Therapy

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Since the relapse rate of DLBCL to frontline chemoimmunotherapy and salvage autologous hematopoietic cell transplant is high, CD19-directed chimeric antigen receptor (CAR) T-cell therapy was adopted. Given the time interval needed for CAR T cells to be manufactured (3-5 weeks) and the aggressiveness of these relapsed/refractory lymphomas, some patients do not make it to the CAR T-cell infusion phase. This calls for a bridging therapy to control, debulk, and sensitize the disease during this period. Radiation therapy can serve this purpose and has shown promising results in some studies. Proton therapy, compared to standard radiation therapy, in some locations, can reduce the radiation dose to the organs at risk, which may lead to fewer side effects for patients with lymphomas. Thus, we hypothesize that proton therapy may serve as a promising bridging strategy to CAR T-cell therapy for some patients.

show abstract

Section: Role For Proton Therapymentioning

confidence: 99%

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Saifi

Kharfan‐Dabaja

Zeidan

et al. 2020

International Journal of Particle Therapy

View full text Add to dashboard Cite

show abstract

“…Although such therapies are proved to be beneficial, the five-year survival rates do not exceed 70%, whereas, simultaneously, almost half of the patients become resistant to or experience a relapse following treatment. In these cases, the median overall survival (OS) declines drastically and does not go beyond 10 months [3]. To this extent, second-line treatment like chimeric antigen receptor (CAR) Tcells should be considered in this group of patients.…”

Section: Introductionmentioning

confidence: 99%

Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?

Kanwal¹

2021

Cureus

View full text Add to dashboard Cite

For years, patients with B-cell non-Hodgkin lymphoma (NHL) have been treated with traditional first-line therapies with a fairly acceptable outcome. However, some individuals with relapsed or resistant lymphoma do not respond to those treatments, including chemotherapy, immunotherapy, radiotherapy, and (or) autologous stem cell transplantation. Based on the acquired immunotherapy knowledge, T-cells genetically engineered with chimeric antigen receptors (CARs) seem to offer complete, enduring clinical responses to patients with refractory or relapsed lymphomas. Currently, four autologous CD19-directed CAR T-cell therapies have gained approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, highgrade B-cell lymphoma, and transformed follicular lymphoma, while further CAR T-cell immunotherapies have entered the clinical trials pipeline. This review aims to summarize the efficacy and safety of the FDAapproved CAR T-cell treatments for the relapsed or refractory lymphomas.

show abstract

“…Its evaluation is difficult because of the nature of the disease and its treatment variability; it is also difficult to compare the results of studies from different countries. [7][8][9][10][11][12][13][14][15][16][17][18][19] To our knowledge, no study has focused on the economic burden in NHL survivors (who have at least 5 years of follow-up after treatment initiation), even though this knowledge is essential. Most survivors are elderly with a potential risk of comorbidity development related to their age and the disease itself (persistent and/or long-term adverse events such as fatigue, relapse, and secondary or new primary cancer).…”

Section: Introductionmentioning

confidence: 99%

Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study

Nerich

Guyeux

Henry-Amar³

et al. 2021

Cancer

View full text Add to dashboard Cite

BACKGROUND:No study has focused on the economic burden in non-Hodgkin lymphoma (NHL) survivors, even though this knowledge is essential. This study reports on health care resource use and associated health care costs as well as related factors in a series of 1671 French long-term NHL survivors. METHODS: Health care costs were measured from the payer perspective. Only direct medical costs (medical consultations, outpatient treatments, hospitalizations, and medical transport) in the past 12 months were included (reference year 2015). Multiple linear regression was used to search for explanatory factors of health care costs. RESULTS: In total, 1100 survivors (66%) reported having used at least 1 health care resource, and 867 (52%) reported having used at least 1 outpatient treatment. After the authors accounted for missing data, the mean health care cost was estimated at €702 ± €2221. Hospitalizations and outpatient treatments were the main cost drivers. Sensitivity analyses confirmed the robustness of the results. For the 1100 survivors who reported using at least 1 health care resource, the mean health care cost was €1067 ± €2268. Several factors demonstrated statistically significant relationships with health care costs. For instance, cardiovascular disorders increased costs by 66% ± 16%. In contrast, rituximab or autologous stem cell transplantation as initial therapy had no effect on health care costs. CONCLUSIONS: The consideration of economic constraints in health care is now a reality. This retrospective study reports on a better understanding of health care resource use and associated health care costs as well as related factors. It may help health care professionals in their ongoing efforts to design personcentered health care pathways.

show abstract

Cost burden of diffuse large B-cell lymphoma

Cited by 15 publications

References 136 publications

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?

Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?

Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study

Contact Info

Product

Resources

About